期刊文献+

癌胚抗原启动子调控融合自杀基因yCDglyTK载体的构建及其应用研究 被引量:3

Construction of carcino-embryonic antigen promotor controls the novel fusion suicide gene yCDglyTK and its application
下载PDF
导出
摘要 目的构建靶向性基因治疗载体pcDNA3.1(-)CVyCDglyTK,研究癌胚抗原(CEA)启动子是否能控制新型融合自杀基因yCDglyTK在CEA阳性结肠癌细胞中专一性表达和杀伤作用。方法采用PCR、RT-PCR、融合PCR、酶切、连接等技术构建由CEA启动子、CMV增强子驱动的融合自杀基因pcDNA3.1(-)CVyCDglyTK表达载体和分别由CEA启动子和巨细胞病毒(CMV)增强子驱动的融合自杀基因pcDNA3.1(-)CEAyCDglyTK、pcDNA3.1(-)CMVyCDglyTK表达载体,以磷酸钙纳米为载体分别转染CEA阳性的人结肠癌细胞株LOVO细胞和CEA阴性的Hela细胞,采用RT-PCR、免疫荧光法检测感染细胞中yCDglyTK基因的表达,并用MIT法检测感染后细胞对5-氟胞嘧啶(5-FC)的敏感性。结果LOVO细胞在感染以上三种质粒表达载体后均有yCDglyTKmRNA表达,且对5-FC的敏感性明显增强,Hela细胞在纳米-pcDNA3.1(-)CMVyCDglyTK复合物感染后有yCDglyTKmRNA表达,对5-FC的敏感性增强,而在纳米-pcDNA3.1(-)CEAyCDglyTK及纳米-pcDNA3.1(-)CVyCDglyTK复合物感染后则没有yCDglyTKmRNA表达,5-FC对其亦无杀伤作用。结论该实验构建的由CEA启动子、CMV增强子驱动的融合自杀基因yCDglyTK靶向性基因治疗载体,能使融合自杀基因在CEA阳性细胞中专一性表达,从而达到靶向治疗肿瘤的目的。 [Objective] To construct targeted plasmid vector pcDNA3.1 (-)CV yCDglyTK and study whether carcino-Embryonic Antigen promotor determines the specific expression of the novel fusion suicide gene and specific lethal effect in CEA-producing colorectal carcinoma cells. [Methods] We constructed the expression plasmid vector of peDNA3.1 (-)CVyCDglyTK controlled under CEA promoter and cytomegalovirus(CMV) enhancer;, pcDNA3.1 (-) CEAyCDglyTK controlled under CEA promoter and pcDNA3.1 (-)CMVyCDglyTK controlled under CMV enhancer, with PCR, PT-PCR, confusion PCR, enzyme restriction, ligation and so on. We combined the calcium phosphate nanoparticles(CPNP) with suicide gene yCDglyTK for transfection the CEA-Positive cells (LOVO) and CEA-negative cells(Hela) respectively; The expression of the yCDglyTK gene was detected by RT-PCR and immunofluoreseenee Assay, MTT analysis was used to detect the eytotoxie effects of the yCDglyTK/5-FC system. [Results] The CEAproducing cells (human eoloreetal eareionma line LOVO cell) showed yCDglyTK mRNA expression and were sensitive to 5-Fe after infection with CPNP- peDNA·CV·yCDglyTK and CPNP-peDNA·CEA·yCDglyTK, CPNP-peDNA·CMV·yCDglyTK, respectively;However,the CEA-negative eells(Hela cell) had no effect and yCDglyTK mRNA expression. After infection with CPNP-peDNA-CV.yCDglyTK,CPNP-peDNA-CEA-yCDglyTK.but expressed yCDglyTK mRNA and sensitive to 5-FC after infection with CPNP- pcDNA·CMV·yCDglyTK. [Conclusion] The targted plasmid vector of pcDNA3. 1(-)CVCDglyTK controlled under CEA promoter and CMV enhancer could control the expression of fusion suicide gene in CEA-positive colorectal careionma cell, to achieve for target cancer gene therapy.
出处 《中国医学工程》 2006年第2期120-124,共5页 China Medical Engineering
基金 中南大学博士创新基金资助课题(0575240)
关键词 癌胚抗原 纳米载体 自杀基因 增强子 结肠癌 calcium phosphate nanoparticles suicide gene gene therapy
  • 相关文献

参考文献1

二级参考文献50

  • 1Das S, Yu L, Gaitatzes R,et al. Biology's new Rosetta stone[J]. Nature,1997, 385(6611): 29-30.
  • 2Luo D, Saltzman W M. Synthetic DNA delivery systems [J]. Nat Biotech,2000, 18:33-37
  • 3Anderson W F. Human gene therapy[J]. Nature, 1998, 392(6679 suppl): 25-30.
  • 4Vijiayanathan V, Thomas T, Thomas TJ. DNA nanoparticles anddevelopment of DNA delivery vehicles for gene therapy [J]. Biochemistry,2002, 41(48): 14085.
  • 5Chen Y, Xue Z, Zheng D, et al. Sodium chloride modified silica nanoparticles as a non viral vector with a high efficiency of DNA transfer into cells[J]. Curr Gene Ther, 2003, 3(3): 273.
  • 6Cristiano R J. Targeted, non-viral gene delivery for cancer gene therapy[J]. Front Biosci, 1998, 3 ( 10 ): D1161-1170.
  • 7Davis S S. Biomedical application of nanotechnology implications for drug targeting and gene therapy[J]. Trends in Biotech, 1997, 15(2):217-224.
  • 8Lambert G, Fattal E, Couvereur P. Nanoparticulate system for the delivery of antisense oligonucleotides[J]. Adv Drugs Deliv Rev, 2001,47(1): 99-112.
  • 9Haenster J, Szoka F C Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture[J]. Bioconjug Chem, 1993, 4:372-379.
  • 10Lambert G, Fattal E, Pinto-Alphandary H, et al. Polyiso- butylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligo- nucleotides[J]. Pharm Res. 2000, 17:707-714.

共引文献4

同被引文献43

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部